The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients
Abstract
SETTING: Tuberculosis (TB) program, Damien Foundation Projects, Bangladesh. OBJECTIVE: To summarize the outcome and its determinants of the first treatment for multidrug-resistant TB using a standardized regimen consisting of a minimum 9 months. DESIGN: This was a prospective, observational study of a gatifloxacin (GFX) based directly observed regimen, mainly with initial hospitalization. The 4-month intensive phase was extended until sputum smear conversion. Patients were monitored using culture for up to 2 years after treatment completion. RESULTS: Of the 515 patients who met the study inclusion criteria and were successively enrolled from 2005 to 2011, 84.4% had a bacteriologically favorable outcome. Due to extensive disease with delayed sputum conversion, only half of the patients completed treatment within 9 months; however, 95% were able to complete treatment within 12 months. Eleven patients failed or relapsed, and 93.1% of the 435 patients who were successfully treated completed at least 12 months post-treatment follow-up. The strongest risk factor for a bacteriologically unfavorable outcome was high-level fluoroquinolone (FQ) resistance, particularly when compounded by initial pyrazinamide (PZA) resistance. Low-level FQ resistance had no unfavorable effect on treatment outcome. Amplification of drug resistance occurred only once, in a patient strain that was initially only susceptible to kanamycin and clofazimine. CONCLUSION: The excellent outcome of the Bangladesh regimen was largely maintained. Bacteriological treatment failures and relapses were rare, except among patients with high-level GFX resistance, notably in the presence of PZA resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kamerbeek, J., Schouls, L., Kolk, A., van Agterveld, M., van Soolingen, D., Kuijper, S., Bunschoten, A., Molhuizen, H., Shaw, R., Goyal, M., et al. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.4.907-914.1997 · Cited by 2,858
Supply, P., Allix, C., Lesjean, S., Cardoso-Oelemann, M., Rüsch-Gerdes, S., Willery, E., Savine, E., de Haas, P., van Deutekom, H., Roring, S., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.01392-06 · Cited by 1,274
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
Falzon, D., Jaramillo, E., Schünemann, H. J., Arentz, M., Bauer, M., Bayona, J., Blanc, L., Caminero, J. A., Daley, C. L., Duncombe, C., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00073611 · Cited by 1,100
Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis
Van Deun, A., Maug, A. K. J., Salim, M. A. H., Das, P. K., Sarker, M. R., Daru, P., & Rieder, H. L. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0077oc · Cited by 647
Self-citationOutpatient gatifloxacin therapy and dysglycemia in older adults.
Park-Wyllie, L. Y., Juurlink, D. N., Kopp, A., Shah, B. R., Stukel, T. A., Stumpo, C., Dresser, L., Low, D. E., & Mamdani, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055191 · Cited by 367
Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis.
Laserson, K. F., Thorpe, L. E., Leimane, V., Weyer, K., Mitnick, C. D., Riekstiņa, V., Zarovska, E., Rich, M., Fraser, H., Alarcon, E., et al. (2005) · PubMed · Cited by 292
Pietersen, E., Ignatius, E., Streicher, E. M., Mastrapa, B., Padanilam, X., Pooran, A., Badri, M., Lesosky, M., van Helden, P., Sirgel, F. A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62675-6 · Cited by 246
Peloquin, C. A., Hadad, D. J., Molino, L. P. D., Palaci, M., Boom, W. H., Dietze, R., & Johnson, J. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01036-07 · Cited by 185
Salimullah, M., Tahera, Y., Siddiqui, M. A., Salam, M. A., Rumi, M. A. K., Huq, F., & Hassan, M. S. (2000) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(00)90319-5 · Cited by 3
Cited by
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Nahid, P., Mase, S. R., Migliori, G. B., Sotgiu, G., Bothamley, G. H., Brozek, J. L., Cattamanchi, A., Cegielski, J. P., Chen, L., Daley, C. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201909-1874st · Cited by 462
World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update
Falzon, D., Schünemann, H. J., Harausz, E., González-Angulo, L., Lienhardt, C., Jaramillo, E., & Weyer, K. (2017) · European Respiratory Journal · doi:10.1183/13993003.02308-2016 · Cited by 420
Tiberi, S., du Plessis, N., Walzl, G., Vjecha, M. J., Rao, M., Ntoumi, F., Mfinanga, S., Kapata, N., Mwaba, P., McHugh, T. D., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30110-5 · Cited by 396
Horsburgh, C. R., Barry, C. E., & Lange, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1413919 · Cited by 323
Practical Guidance for Clinical Microbiology Laboratories: Mycobacteria
Forbes, B. A., Hall, G. S., Miller, M. B., Novak, S. M., Rowlinson, M.-C., Salfinger, M., Somoskövi, A., Warshauer, D. M., & Wilson, M. L. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00038-17 · Cited by 311
Metadata
- Authors
- Aung, K. J. M., Van Deun, A., Declercq, E., Sarker, M. R., Das, P. K., Hossain, M. A., & Rieder, H. L.
- Venue
- The International Journal of Tuberculosis and Lung Disease
- Published
- 2014-10-01
- Volume
- 18
- Issue
- 10
- Pages
- 1180-1187
- ISSN
- 1027-3719 (ISSN-L)
- 1815-7920
- OpenAlex
- W2052166920
- Cited by
- 318
- References
- 9
- FWCI
- 26.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients. https://app.cochat.ai/papers/10.5588/ijtld.14.0100
- The paper
- Aung, K. J. M., Van Deun, A., Declercq, E., Sarker, M. R., Das, P. K., Hossain, M. A., & Rieder, H. L. (2014). Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients. The International Journal of Tuberculosis and Lung Disease. https://doi.org/10.5588/ijtld.14.0100
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.